Aveo Pharmaceuticals Stock Analysis

AVEO -  USA Stock  

USD 3.74  0.01  0.27%

The big decline in price over the last few months for Aveo Pharmaceuticals could raise concerns from institutional investors as the firm it trading at a share price of 3.74 on 156,701 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Aveo Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.53. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Aveo Pharmaceuticals partners.
Please continue to Trending Equities.

Aveo Pharmaceuticals Stock Analysis 

The Aveo Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Aveo Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Aveo Pharmaceuticals Stock analysis module also helps to analyze the Aveo Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Aveo Pharmaceuticals Stock Analysis Notes

About 45.0% of the company shares are held by institutions such as insurance companies. The book value of Aveo Pharmaceuticals was presently reported as 1.49. The company has Price/Earnings (P/E) ratio of 158.21. Aveo Pharmaceuticals recorded a loss per share of 1.88. The entity had not issued any dividends in recent years. The firm had 1-10 split on the 20th of February 2020. AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts. Aveo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. For more info on Aveo Pharmaceuticals please contact Michael Bailey at 857 400-0101 or go to www.aveooncology.com.

Aveo Pharmaceuticals Quarterly Cost of Revenue

1.74 MillionShare

Aveo Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aveo Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aveo Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aveo Pharmaceuticals generated a negative expected return over the last 90 days
Aveo Pharmaceuticals has high historical volatility and very poor performance
Aveo Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 25.54 M. Net Loss for the year was (57.59 M) with loss before overhead, payroll, taxes, and interest of (16.66 M).
Aveo Pharmaceuticals currently holds about 94.02 M in cash with (57.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.73.
Latest headline from www.nasdaq.com: AVEO Pharmaceuticals May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - Nasdaq

Aveo Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Aveo Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aveo Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report15th of March 2022
Next Earnings Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End15th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Aveo Pharmaceuticals Largest EPS Surprises

Earnings surprises can significantly impact Aveo Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Aveo Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Aveo Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Aveo Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Aveo Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
1st of December 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
8th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of September 2021
Unclassified Corporate Event
27th of August 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
5th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
16th of July 2021
Financial Statements and Exhibits. Regulation FD Disclosure
9th of June 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
10th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition

Aveo Pharmaceuticals Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Aveo Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aveo Pharmaceuticals backward and forwards among themselves. Aveo Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Aveo Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Edge Wealth Management LlcCommon Shares14.0K
Magnolia Capital Management LtdCommon Shares1000K
Nea Management Company LlcCommon SharesM24.4 M
Aigh Capital Management LlcCommon SharesM12.3 M
J Goldman Co LpCommon Shares1.7 M10.3 M
Adage Capital Partners Gp LlcCommon Shares1.5 M9.3 M
Vanguard Group IncCommon Shares1.5 MM
Group One Trading LpCall Options197.2 K1.2 M
Susquehanna International Group LlpPut Options159.7 K987 K
Note, although Aveo Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aveo Pharmaceuticals Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 140.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aveo Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Aveo Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Aveo Pharmaceuticals Profitablity

Aveo Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Aveo Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Aveo Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aveo Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aveo Pharmaceuticals' profitability requires more research than a typical breakdown of Aveo Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (225.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (219.66) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.2.
Last ReportedProjected for 2022
Return on Investment(112.22) (121.08) 
Return on Average Assets(0.50) (0.54) 
Return on Average Equity(1.25) (1.28) 
Return on Invested Capital(1.99) (2.04) 
Return on Sales(6.49) (7.01) 

Management Efficiency

The entity has return on total asset (ROA) of (38.5) % which means that it has lost $38.5 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (125.94) %, meaning that it created substantial loss on money invested by shareholders. Aveo Pharmaceuticals management efficiency ratios could be used to measure how well aveo pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -121.08. The value of Return on Average Assets is estimated to slide to -0.54. Aveo Pharmaceuticals Average Assets are quite stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 75.17 Million. Tangible Asset Value is expected to rise to about 73.1 M this year, although the value of Net Current Assets as percentage of Total Assets will most likely fall to 77.18.
Last ReportedProjected for 2022
Book Value per Share 1.48  1.52 
Enterprise Value over EBIT(3.60) (3.88) 
Enterprise Value over EBITDA(3.73) (4.03) 
Price to Book Value 4.24  4.57 
Tangible Assets Book Value per Share 2.81  2.88 
Enterprise Value126.7 M145.7 M
Tangible Asset Value60.2 M73.1 M

Technical Drivers

As of the 19th of January, Aveo Pharmaceuticals shows the risk adjusted performance of (0.18), and Mean Deviation of 2.44. Aveo Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Aveo Pharmaceuticals, which can be compared to its rivals. Please confirm Aveo Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Aveo Pharmaceuticals is priced correctly, providing market reflects its regular price of 3.74 per share. Given that Aveo Pharmaceuticals has jensen alpha of (0.82), we suggest you to validate Aveo Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Aveo Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Aveo Pharmaceuticals highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Aveo Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aveo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aveo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aveo Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ledell Jebediah over a month ago via Macroaxis 
Acquisition by Ledell Jebediah of 170000 shares of Aveo Pharmaceuticals subject to Rule 16b-3
Michael Bailey over three months ago via Macroaxis 
Purchase by Michael Bailey of 15000 shares of Aveo Pharmaceuticals
Ferraresso Michael over three months ago via Macroaxis 
Purchase by Ferraresso Michael of 2608 shares of Aveo Pharmaceuticals
Spring Scarlett over six months ago via Macroaxis 
Acquisition by Spring Scarlett of 12500 shares of Aveo Pharmaceuticals subject to Rule 16b-3
Cullen Kevin Joseph over six months ago via Macroaxis 
Acquisition by Cullen Kevin Joseph of 25000 shares of Aveo Pharmaceuticals subject to Rule 16b-3
Lucera Erick over six months ago via Macroaxis 
Acquisition by Lucera Erick of 100000 shares of Aveo Pharmaceuticals subject to Rule 16b-3
Epperly Corinne over six months ago via Macroaxis 
Acquisition by Epperly Corinne of 15000 shares of Aveo Pharmaceuticals subject to Rule 16b-3
Ferraresso Michael over six months ago via Macroaxis 
Aveo Pharmaceuticals exotic insider transaction detected
Epperly Corinne over a year ago via Macroaxis 
Acquisition by Epperly Corinne of 10000 shares of AVEO Pharmaceuticals subject to Rule 16b-3
Spring Scarlett over a year ago via Macroaxis 
Acquisition by Spring Scarlett of 4000 shares of AVEO Pharmaceuticals subject to Rule 16b-3
Growth Equity Opportunities Fund Iv Llc over a year ago via Macroaxis 
Purchase by Growth Equity Opportunities Fund Iv Llc of 1428571 shares of AVEO Pharmaceuticals
Slichenmyer William over a year ago via Macroaxis 
Acquisition by Slichenmyer William of 31900 shares of AVEO Pharmaceuticals subject to Rule 16b-3

Aveo Pharmaceuticals Predictive Daily Indicators

Aveo Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aveo Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aveo Pharmaceuticals Forecast Models

Aveo Pharmaceuticals time-series forecasting models is one of many Aveo Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aveo Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Aveo Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aveo Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aveo Pharmaceuticals shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Aveo Pharmaceuticals. By using and applying Aveo Pharmaceuticals Stock analysis, traders can create a robust methodology for identifying Aveo Pharmaceuticals entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(1.49) (1.61) 
EBITDA Margin(6.49) (7.00) 
Gross Margin 0.90  0.89 
Profit Margin(6.80) (7.34) 
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts. Aveo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.

Current Aveo Pharmaceuticals Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aveo Pharmaceuticals analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aveo Pharmaceuticals analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
19.0Strong Buy4Odds
Aveo Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aveo Pharmaceuticals analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aveo Pharmaceuticals stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aveo Pharmaceuticals, talking to its executives and customers, or listening to Aveo Pharmaceuticals conference calls.
Aveo Pharmaceuticals Analyst Advice Details

Aveo Pharmaceuticals Stock Analysis Indicators

Aveo Pharmaceuticals stock analysis indicators help investors evaluate how Aveo Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aveo Pharmaceuticals shares will generate the highest return on investment. By understating and applying Aveo Pharmaceuticals stock analysis, traders can identify Aveo Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio4.63
Fifty Two Week Low3.9500
Revenue Growth321.50%
Shares Short Prior Month1.57M
Average Daily Volume Last 10 Day516.24k
Average Daily Volume In Three Month302.36k
Shares Percent Shares Out4.73%
Gross Margins-7.52%
Short Percent Of Float5.36%
Forward Price Earnings-10.74
Float Shares28.31M
Fifty Two Week High18.2400
Enterprise Value To Ebitda-2.10
Fifty Day Average5.7920
Two Hundred Day Average6.2859
Enterprise Value To Revenue4.61
Please continue to Trending Equities. Note that the Aveo Pharmaceuticals information on this page should be used as a complementary analysis to other Aveo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Aveo Pharmaceuticals Stock analysis

When running Aveo Pharmaceuticals price analysis, check to measure Aveo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aveo Pharmaceuticals is operating at the current time. Most of Aveo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aveo Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aveo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aveo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Is Aveo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aveo Pharmaceuticals. If investors know Aveo Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aveo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aveo Pharmaceuticals is measured differently than its book value, which is the value of Aveo Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Aveo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aveo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aveo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aveo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aveo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Aveo Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aveo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.